Time to throw in the towel for Abbott on this generation of their Absorb BVS because of slow sales. However, there could still be a platform for this technology…
Abbott halts global sales of 1st-gen Absorb stents
Abbott (NYSE:ABT) said today it will halt global sales of its 1st-generation Absorb bioresorbable vascular scaffold due to low commercial sales.
In a statement on it’s website, the company said it is discontinuing all sizes of the Absorb bioresorbable vascular scaffold system, effective Sept. 14.
While the current product will be taken off the market, the company said that it will continue development of next-generation devices and monitoring of patients in existing clinical trials.
